Obesity drugs under review | ACC calls for more screening | Dexcom issues recall | AI delivers helpful advice | A call to action

The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others.

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote. 

Adults with a history of CVD, type 2 diabetes and stroke were all associated with a lower dementia risk if they ate a whole food, plant-based diet. The study, published in JACC: Advances, was based on data from more than 71,000 U.K. Biobank participants. 

The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.

Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Cardiovascular disease remains the world’s leading cause of death, according to a special report from the American College of Cardiology. The new analysis, described by one cardiologist as a "wake-up call," includes data from more than 200 countries and territories.

AI-powered chatbots can be valuable resources when users have questions about cardiovascular health—but they are still far from perfect.

Researchers tracked real-world data from nearly 60,000 Medicare patients, highlighting the benefits of weekly injections of semaglutide. 

Pediatric cardiologists can make a significant impact on global health trends by looking for early warning signs of CVD in their patients and collaborating with other physicians.

An oral version of the popular GLP-1 drug was associated with multiple benefits, including considerable improvements in BMI and waist circumference. Previous research found that it reduces certain heart risks in patients with type 2 diabetes.